KIT and bladder transitional cell carcinoma: Since the assessment of markers in combination may perform better than those considered individually, therefore, in order to emphasize the prognostic value of new targeted therapeutic agent in bladder urothelial carcinoma, we immunohistochemically examined the expression of CD117/KIT, HER2, and ERβ in 2 groups of Egyptian patients suffering from urothelial carcinoma either schistosomally related or not.